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ABSTRACT
Background: Tenascin-C and fibronectin are adhesive glycoproteins modulating 
the structure of the extracellular matrix and cellular functions. Their expression and 
function in esophageal adenocarcinoma is poorly known. The aim of this study was to 
evaluate the expression of tenascin-C and fibronectin in esophageal adenocarcinoma 
and its precursor stages.
Results: Stromal tenascin-C and fibronectin expression were found in all evaluated 
lesion types. Expression of both molecules increased from gastric metaplasia towards 
adenocarcinoma (p<0.05). In carcinomas, tenascin-C expression in the bulk was 
associated with T-stage (p=0.006), presence of lymph node (p=0.004) and distant 
organ metastases (p=0.007). Abundant tenascin-C expression associated with poor 
survival (p=0.034) in univariate analysis. Fibronectin expression associated to T-stage 
(p=0.030). Expression of tenascin-C or fibronectin in the tumor invasive front was not 
associated to clinicopathological variables or survival. No significant correlation with 
tumor/stroma percentage, cancer-associated fibroblasts or mean vascular density 
was observed with either tenascin-C or fibronectin.
Methods: Tenascin-C and fibronectin were stained immunohistochemically and 
assessed in esophageal specimens from patients with esophageal adenocarcinoma 
(n=90) or dysplasia (n=30). Structures and lesion were evaluated including 
normal esophagus (n=77), gastric (n=61) or intestinal (n=51) metaplasia without 
dysplasia, and low-grade (n=42) or high-grade (n=34) dysplasia, and esophageal 
adenocarcinoma (n=90). In carcinomas, both bulk and invasive front were separately 
evaluated. In addition, tumor/stroma percentage, cancer-associated fibroblasts and 
mean vascular density were evaluated.
Conclusions: Tenascin-C and fibronectin are upregulated in esophageal 
adenocarcinoma when compared to Barrett’s esophagus and dysplasia. Increased 
tenascin-C expression is associated with metastasis and poor prognosis in esophageal 
adenocarcinoma.
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INTRODUCTION
The incidence of esophageal adenocarcinoma has 
been increasing rapidly in the Western World during 
the last decades. Its relative rareness and aggressive 
nature makes it a disease with late diagnosis and poor 
survival rate [1]. To improve the prognosis of esophageal 
adenocarcinoma, early identification of premalignant 
lesions would be beneficial.
Tenascins are a family of large adhesive of 
glycoproteins of the extracellular matrix that affect tissue 
elasticity and architecture and cellular responses [2]. A 
member of this family, tenascin-C, has an essential role 
in morphogenesis of blood vessels during embryonic 
development but its distribution in adult tissues is typically 
limited. However, re-expression of tenascin-C occurs in 
injured tissues and in pathological remodeling in various 
diseases, such as cancer [2]. Increased expression of 
tenascin-C has been detected in several types of benign 
and malignant neoplasms, and is found to associate to the 
invasive and metastatic potential of malignant tumors, 
for example esophageal squamous cell carcinoma and 
colorectal cancer [3, 4]. A single study has reported no 
expression of tenascin-C in 6 patients with Barrett’s 
esophagus and upregulation of tenascin-C in 15 patients 
with esophageal adenocarcinoma, showing association to 
poor tumor differentiation [5].
Fibronectin is another high-molecular-weight 
adhesive glycoprotein of the extracellular matrix with 
elevated expression mainly in embryonic tissues, wound 
healing, inflammation and a variety of tumors, suggesting 
a role in tissue remodeling [2]. Fibronectin is believed 
to promote proliferation and survival of tumor cells, 
and to have a role in tumor invasion and metastases in 
lung, breast and colorectal cancer [6–8]. No published 
information on tenascin-C or fibronectin in esophageal 
adenocarcinoma or its precursor stages could be found in 
larger patient cohorts.
The aim of the study was to determine the 
expression of tenascin-C and fibronectin in esophageal 
adenocarcinoma and its precursor stages, and to evaluate 
if the molecules could be used as prognostic factors or as 
biomarkers of premalignant lesions.
RESULTS
Both tenascin-C and fibronectin were distinctly 
expressed in the lamina propria of normal esophageal 
mucosa covered by squamous epithelium and in the 
lamina or stroma of all evaluated lesion types, including 
intestinal and gastric metaplasia, low- and high-grade 
dysplasia and adenocarcinoma (Figures 1 and 2). The 
expression of both molecules increased significantly 
from gastric metaplasia towards adenocarcinoma. 
Generally expression of tenascin-C was higher than that 
of fibronectin. Stromal expression levels in the evaluated 
lesions are summarized in Table 1. For both molecules, 
cytoplasmic expression in epithelial cells was very rare 
in normal, metaplastic and neoplastic epithelia and did 
not associate to any of the clinicopathological variables. 
Epithelial tenascin-C expression occurred in 16/354 and 
that for fibronectin in 7/354 of the evaluated lesions, and 
there was no association with the lesion type (data not 
shown).
Most typically, in both types of metaplasia and 
dysplasia stromal expression of tenascin-C and fibronectin 
was mainly restricted to lamina propria and the underlying 
connective tissue (Figure 1). In adenocarcinoma the 
stromal expression of both molecules was more diffuse 
and the molecules could be identified not only in the 
middle of the tumor but also in the tumor surrounding 
stroma (Figure 2).
Tenascin and fibronectin in normal esophageal 
mucosa
Expression of tenascin-C in normal mucosa was 
present in the subepithelial layer and occasionally around 
the glands (Figure 1). Stromal expression of tenascin-C in 
normal mucosa was higher than in Barrett’s esophagus or 
dysplasia, and nearly similar compared to adenocarcinoma 
(Figures 1 and 2; Table 1).
Fibronectin was only scantily expressed in normal 
mucosa with locations similar to those of tenascin-C 
(Figure 1). Expression levels were similar to that in 
gastric and intestinal metaplasia and in low- and high-
grade dysplasia. Statistically significant difference was 
observed only in comparison between normal epithelium 
and adenocarcinoma (Table 1).
Tenascin-C and fibronectin in Barrett’s 
esophagus and dysplasia
The expression of both of the molecules was lowest 
in gastric metaplasia and increased gradually towards 
high-grade dysplasia. The expression was localized in 
lamina propria and was also seen in the mucosa (Figure 
1). The increase from metaplasia to dysplasia was 
greater with tenascin-C, although only the difference 
between gastric metaplasia and high-grade dysplasia 
was statistically significant. No statistically significant 
differences in fibronectin expression were observed 
between the premalignant lesions (Table 1).
Tenascin-C and fibronectin in esophageal 
adenocarcinoma
Stromal expression of both tenascin-C and 
fibronectin was highest in adenocarcinoma (Figure 
2). The expression of tenascin-C was statistically 
significantly elevated when compared to all other lesion 
types, except normal epithelium. Fibronectin expression in 
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adenocarcinoma showed distinct increase when compared 
to all other lesion types.
Expression in the invasive front was higher than 
in tumor bulk stroma mean difference of tenascin-C 
expression being 0.7 (95% CI 0.3-1.1; p<0.001) and that 
of fibronectin 0.7 (95% CI 0.4-1.0; p<0.001; Table 1).
Relation with clinicopathological variables and 
cancer survival
Tenascin-C expression in the tumor bulk stroma 
was associated with several clinocopathological variables 
(Table 2) including high T-class (p=0.006), lymph 
node (p=0.004) and organ metastases (p=0.007). High 
expression of fibronectin in the tumor bulk stroma was 
associated to only high T-class (p=0.030). Tenascin-C 
expression in the tumor bulk stroma associated to cancer 
survival in the univariate analysis, high expression 
indicating poor prognosis (log rank p=0.034; Figure 3). In 
contrast, tenascin-C or fibronectin expression in the tumor 
invasive front was not associated with clinicopathological 
variables or cancer survival (Table 2). Multivariate 
analysis did not show statistically significant associations 
between tenascin-C or fibronectin expression and survival.
Figure 1: Typical expressions patterns of tenascin-C (a, c, e) and fibronectin (b, d, f) in normal esophageal mucosa (a, b) and premalignant 
lesions of adenocarcinoma, including intestinal (c) and gastric (d) metaplasia and high-grade (e, f) dysplasia. Magnification 10x, scale bar 
100 μm.
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Tumor/stroma percentage – relation with 
clinicopathological variables, cancer survival 
and correlation with stromal tenascin-C and 
fibronectin
Both mean and median tumor/stroma percentage in 
90 patients with adenocarcinoma were 55% (SD 22). No 
association to TNM-staging or grade of differentiation was 
observed whether analyzing in two (cut-off 50%) or four 
(cut-offs 25, 50, 75%) groups. Similarly, no association 
to survival was observed (in two groups p=0.983, four 
groups p=0.869). We observed no correlation with 
tenascin-C and fibronectin experssion with tumor/stroma 
percentage (Table 3).
Correlation of stromal tenascin-C, fibronectin 
and α-SMA
Cancer-associated fibroblasts (CAFs), identified 
by intracellular α-SMA, are known predictors of poor 
Figure 2: Typical expression patterns of tenascin-C (a, c, e) and fibronectin (b, d, f) in esophageal adenocarcinoma. Highly variable 
immunostaining stromal density was observed in tumor stroma of both tenascin-C (a, c) and fibronectin (b, d). The tumor’s invasive front 
showed high expression of both molecules (e, f). Magnification 10x, scale bar 100 μm.
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prognosis in various malignancies with highly similar 
staining pattern as tenascin-C and fibronectin [9, 10]. In 
12 selected patient samples, mean α-SMA expression 
in tumor bulk was 1.9 (SD 1.0) and in tumor invasive 
front 2.2 (SD 0.8). Overlap with tenascin-C and α-SMA 
was observed in tumor bulk (26% (SD 32)), and tumor 
invasive front (13% (SD 15)). Similarly, overlap was seen 
with fibronectin and α-SMA (42% (SD 46), 56% (SD 44), 
respectively), Figure 4. Stromal cells in the tumor bulk 
showed occasional cytoplasmic positivity of both markers 
(Figure 4). However, no statistically significant correlation 
in tenascin-C or fibronectin expression and α-SMA was 
observed (Table 3).
Correlation of stromal tenascin-C, fibronectin 
and vascular density
CD31 staining for analysis of mean microvascular 
density was performed to 20 randomly selected patients. 
Mean number of vessels per single high power field (20x 
magnification) in tumor bulk was 48 (SD 20) and in tumor 
invasive front 56 (SD 33). We observed no correlation 
Table 1: Stromal expression of tenascin-C and fibronectin in normal esophageal mucosa and in different esophageal 
lesions
Tenascin-C
Stroma Invasive front (carcinoma)
Mean 95% CI Statistical 
significance
Mean 95% CI Statistical 
significance
Normal mucosa 1.8 1.6-2.0
Gastric metaplasia 0.9 0.7-1.1 a
Intestinal 
metaplasia 1.0 0.7-1.3 a
Low-grade 
dysplasia 1.1 0.8-1.4 a
High-grade 
dysplasia 1.6 1.2-2.0 b
Adenocarcinoma 1.9 1.7-2.2 bcd 2.3 2.0-2.6 f
Fibronectin
Normal mucosa 0.8 0.7-1.0
Gastric metaplasia 0.6 0.5-0.8
Intestinal 
metaplasia 0.8 0.6-1.0
Low-grade 
dysplasia 0.8 0.5-1.0
High-grade 
dysplasia 1.0 0.7-1.3
Adenocarcinoma 1.5 1.3-1.7 abcde 2.1 1.8-2.3 f
Density of stromal expression was assessed with a five point scale from negative (0) to very high density (4). Values are 
presented as mean and 95% confidence interval (CI). Statistical testing was performed with One way ANOVA with Tukey 
in post hoc analysis and paired sample t-test.
a compared to normal mucosa, p<0.05.
b compared to gastric metaplasia, p<0.05.
c compared to intestinal metaplasia, p<0.05.
d compared to low-grade dysplasia, p<0.05.
e compared to high-grade dysplasia, p<0.05.
f comparison between intralesional adenocarcinoma stroma and invasive front.
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Table 2: Expression of tenascin-C and fibronectin in the tumor bulk stroma and invasive front region compared to 
clinicopathological variables in esophageal adenocarcinoma
Variable n/N
Tenascin-C bulk, n (%) Tenascin-C front, n (%) Fibronectin bulk, n (%) Fibronectin front, n (%)
Low High p Low High p Low High p Low High P
pT
T1 14/89 12 (23) 2 (5) 0.006 7 (21) 4 (15) 0.884 6 (13) 8 (19) 0.030 8 (22) 3 (12) 0.451
T2 13/89 7 (13) 6 (16) 6 () 4 (15) 6 (13) 7 (16) 5 (14) 5 (19)
T3 48/89 30 (58) 18 (49) 18 (55) 17 (63) 31 (67) 17 (40) 19 (53) 17 (65)
T4 14/89 3 (6) 11 (30) 2 (6) 2 (7) 3 (7) 11 (26) 4 (11) 1 (4)
Lymph nodes
negative 35/89 27(52) 8 (22) 0.004 19 (58) 10 (37) 0.113 19 (41) 16 (37) 0.693 19 (53) 11 (42) 0.416
positive 54/89 25 (48) 29 (78) 14 (42) 17 (63) 27 (59) 27 (63) 17 (47) 15 (58)
Organ metastases
negative 62/89 42 (81) 20 (54) 0.007 28 (85) 24 (89) 0.647 32 (70) 30 (70) 0.983 31 (86) 23 (88) 0.785
positive 27/89 10 (19) 17 (46) 5 (15) 3 (11) 14 (30) 13 (30) 5 (14) 3 (12)
Grade
Well-
differentiated 29/90 21(40) 8 (22) 0.116 15 (45) 8 (30) 0.311 13 (28) 16 (37) 0.623 15 (42) 8 (31) 0.386
Moderately 
differentiated 23/90 14 (26) 9 (24) 6 (18) 9 (33) 13 (28) 10 (23) 7 (19) 9 (35)
Poorly 
differentiated 38/90 18 (34) 20 (54) 12 (36) 10 (37) 21 (45) 17 (40) 14 (39) 9 (35)
Stage
I 14/89 11 (21) 3 (8) 0.038 8 (24) 4 (15) 0.701 5 (11) 9 (21) 0.491 10 (28) 2 (8) 0.239
II 36/89 24 (46) 12 (32) 17 (52) 16 (59) 21 (46) 15 (35) 18 (50) 15 (58)
III 12/89 7 (13) 5 (14) 3 (9) 4 (15) 7 (15) 5 (12) 4 (11) 5 (19)
IV 27/89 10 (19) 17 (46) 5 (15) 3 (11) 13 (28) 14 (33) 4 (11) 4 (15)
Tumor size
small 
(<40mm)
36/88 23 (44) 13 (36) 0.446 12 (36) 12 (44) 0.525 19 (41) 17 (40) 0.937 14 (39) 11 (42) 0.787
large 
(≥40mm)
52/88 29 (56) 23 (64) 21 (64) 15 (56) 27 (59) 25 (60) 22 (61) 15 (58)
Significant p-values are shown in bold. High expressions was defined as ≥3.
with tenascin-C or fibronectin expression and microvessel 
density (Table 3).
DISCUSSION
We demonstrate the expression of tenascin-C 
and fibronectin in normal esophageal mucosa and 
in columnar metaplasia-dysplasia-adenocarcinoma-
sequence of Barrett’s esophagus. Stromal expression 
of both of the molecules showed stepwise increase 
from metaplasia towards esophageal adenocarcinoma. 
Tenascin-C expression was generally more abundant than 
fibronectin and high Tenascin-C expression in the tumor 
stroma significantly associated with advanced TNM-stage 
and poor prognosis. High fibronectin expression was 
associated with advanced T-stage.
Strength of the current study is homogenous study 
population from single geographical area of Northern 
Finland from 1987 to 2013 with no apparent selection 
bias. Interobserver agreement was excellent with no 
required re-evaluations. Possible weakness is the use 
of immunohistochemistry as the only method in the 
evaluation of tenascin-C and fibronectin expression. 
However, strict validation of the used antibodies was 
performed and the inverse association with tenascin-C 
expression and survival with solid biological background 
Oncotarget66871www.impactjournals.com/oncotarget
in cancer metabolism reduces the possibility of chance 
findings.
Based on our results, tenascin-C expression is 
upregulated in stroma of esophageal adenocarcinoma 
when compared to gastric and intestinal metaplasia and 
low- and high-grade dysplasia. Several previous studies 
have demonstrated that the high tenascin-C expression in 
the tumor microenvironment is caused by its increased 
synthesis in myofibroblasts [11]. It has also been 
reported that cancer cells in micrometastases act as the 
main source of tenascin-C in the tumor until the tumor 
stroma can take over the tenascin-C production [12]. By 
expressing tenascin-C, the cancer cells may support their 
own ability to metastasize. In our study, intracellular 
staining for tenascin-C in the cancer cells as a possible 
indicator of synthesis was rare and no association with 
clinicopathological features was seen. In oral tongue 
squamous cell carcinoma, a similar staining pattern of 
CAFs with tenascin-C, fibronectin has been previously 
observed [10, 13]. With a pilot series of 12 patients 
we observed overlap of tenascin-C, fibronectin and 
α-SMA expressions in tumor stroma and in cytoplasm of 
stromal cells suggesting that myofibroblasts contribute 
to stromal tenascin-C and fibronectin synthesis. In 
agreement with our results, tenascin-C expression has 
usually been observed in the tumor stroma [14]. Its 
distribution is determined primarily by location of the 
cells that secrete it, but it is probable that its binding 
to specific proteins, for example collagens, is also 
involved [15].
Previous studies have suggested that tenascin-C 
could be used as a biomarker of tumor invasion 
and metastasis and as a prognostic factor in various 
cancers [3, 4]. It has also been investigated as a target 
for therapy [16]. In colorectal cancer myofibroblasts 
in stroma of invasive tumor front secrete tenascin-C 
and stimulate cancer cell invasion [11, 17]. In our 
study, tenascin-C and fibronectin expression were 
significantly increased in the tumor invasive front as 
compared to the tumor bulk stroma without showing 
Figure 3: Kaplan-Meier survival curve showing esophageal adenocarcinoma survival divided by low and high (≥3) 
tenascin-C expression density.
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Figure 4: Double staining of tenascin-C (brown) and α-smooth muscle actin (α-SMA, gray) (a). Fibronectin and α-SMA (b). Magnification 
10x, scale bar 100 μm. High magnification (20x) images in the right upper corner show stromal cells in the tumor bulk with cytoplasmic 
positivity of both markers.
Table 3: Correlations of tenascin-C and fibronectin expression with tumor/stroma percentage, α-smooth muscle actin 
(α-SMA) and vascular density (CD31) with two-tailed Spearman’s correlation test
Tenascin-C bulk Tenascin-C front Fibronectin bulk Fibronectin front
Correlation coefficient (p-value)
Tumor/stroma 
percentage, n=90
0.096 (p=0.367) -0.050 (p=0.704) 0.130 (p=0.221) 0.028 (p=0.831)
α-SMA, n=12 0.113 (p=0.727) -0.111 (p=0.759) 0.118 (p=0.716) 0.211 (p=0.558)
CD31, n=20 0.168 (p=0.465) -0.357 (p=0.133) 0.175 (p=0.448) -0.047 (p=0.843)
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any association with clinicopathological variables. In 
contrast, the expression of tenascin-C in the tumor bulk 
of esophageal adenocarcinoma tumors was related to 
higher TNM-stage. The mechanisms for the association 
of abundant tenascin-C with adverse cancer prognosis 
may lie in its various mechanisms affecting both the 
structure of extracellular matrix and functions of cancer 
cells. Previously, high tenascin-C expression has been 
shown to associate to poor cellular differentiation, 
although with limited patient material [5]. Tenascin-C 
is able to influence cancer growth by affecting cell 
adhesion and migration, but also by influencing the 
Table 4: Baseline characteristics of the patients with esophageal adenocarcinoma, high grade dysplasia and low-
grade dysplasia
Patient clinical 
data
EAC
N=90
HGD
N=10
LGD
N=20
Age at diagnosis n/N % n/N % n/N %
<60 yrs 32/90 35.6 5/10 50 4/20 20
60-65yrs 18/90 20.0 3/10 30 3/20 15
>65 yrs 40/90 44.4 2/10 20 13/20 65
Sex
Male 74/90 82.2 10/10 100 13/20 65
Female 16/90 17.8 0/10 0 7/20 35
Tumor grade
Well-
differentiated 29/90 32.2
Moderately 
differentiated 23/90 25.6
Poorly 
differentiated 38/90 42.2
T-classification
I 14/89 15.7
II 13/89 14.6
III 48/89 53.9
IV 14/89 15.7
Lymph nodes
Negative 35/89 39.3
Positive 54/89 60.7
Distant metastases
Negative 62/89 69.7
Positive 27/89 30.3
Tumor stage
I 14/89 15.7
II 36/89 40.4
III 12/89 13.5
IV 27/89 30.3
Total of 90 patients with adenocarcinoma, 10 patients with high-grade dysplasia and 20 patients with low-grade dysplasia 
are presented in the Table. TNM classification was available only from 89 patients.
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expression of tumor suppressor genes, oncogenes and 
genes involved in the maintenance of genomic stability 
[18, 19]. It is also known to have a role in loss of 
intercellular adhesion [20], enhancing cell migration and 
metastasis of tumor cells. In our study, no correlation 
with vascular density and tenascin-C or fibronectin 
expression was observed, suggesting that prognostic 
effect of tenascin-C is not related with induction of 
angiogenesis. Why expression patterns only in the tumor 
bulk stroma and not in the invasive front were associated 
to poor prognosis, is unclear. Based on largely constant 
abundant expression of tenascin-C in the invasive 
front (Table 1), we speculate, that the expression in the 
invasive front might be upregulated by the process of 
invasion itself, while expression patterns in the tumor 
bulk might be more representative of those properties of 
tumor cells important in the distant disseminaton.
Fibronectin showed a similar pattern of 
upregulation as tenascin-C in adenocarcinoma 
samples. Expression in normal mucosa, both types of 
metaplasia and dysplasia was more or less the same 
and only adenocarcinoma differed significantly from 
all other lesion types. Fibronectin controls a variety of 
physiological functions, including cell adhesion, cell 
migration, cell differentiation, tissue repair and cell 
proliferation [8]. Fibronectin stimulates cell growth 
and reduces apoptosis through integrin α5β1 activation, 
cyclooxygenase-2 induction and by inhibiting cyclin-
dependent kinase inhibitor p21Waf1/Cip1 gene expression 
[21]. It also activates several kinase-signaling pathways 
of which are not shared by other matrix components 
[6]. It has been earlier shown that the adhesion of lung 
carcinoma cells to fibronectin reduces apoptosis induced 
by standard chemotherapeutic agents and enhances 
tumorigenicity [22], which supports the hypothesis 
that fibronectin could have value as a therapeutic target 
in cancers [23]. Our results indicate that fibronectin 
expression increases with the progression of esophageal 
adenocarcinoma and that its high expression associates to 
T-stage of the tumor. In agreement with several previous 
studies, it seems that fibronectin is related to cancer 
development and growth.
In our study tumor/stroma percentage showed no 
association to clinicopathological variables or survival. 
Previously one study in esophageal adenocarcinoma has 
suggested that low (<50%) percentage indicates poor 
prognosis [24]. On the contrary, in colorectal cancer high 
tumor/stroma percentage was associated to a reduced 
cancer-specific survival [25]. More studies are needed 
to assess the significance of tumor/stroma percentage 
in esophageal cancer. Interestingly, we observed no 
correlation with tumor/stroma percentage and tenascin-C 
or fibronectin expression, suggesting that the size of 
stromal area does not affect tenascin-C or fibronectin 
density.
In conclusion, our results indicate that both 
tenascin-C and fibronectin are highly expressed in the 
stroma of esophageal adenocarcinoma and that expression 
in the precursor stages, including Barrett’s esophagus 
and dysplasia, is low compared to the cancer tissue. In 
addition, the results show that high tenascin-C expression 
in tumor stroma associates with advanced disease and 
reduced survival, and could therefore be used as a 
biomarker for esophageal adenocarcinoma with poor 
prognosis.
MATERIALS AND METHODS
Patients
Paraffin-embedded archival specimens of 
adenocarcinoma or esophageal dysplasia were collected 
from the Department of Pathology, Oulu University 
Hospital, between years 1987-2013, with follow-up until 
the end of 2015 or death. The final series consisted of 90 
patients with esophageal adenocarcinoma, 10 with high-
grade dysplasia and 20 with low-grade dysplasia as the 
most advanced lesion. Of the carcinoma specimens, 26 
(29%) were biopsies and 64 (71%) surgical specimens. 
The material has been previously described elsewhere 
[26–28]. Out of 90 patients with carcinoma, four received 
neoadjuvant chemoradiotherapy. The median age of the 
patients with adenocarcinoma was 64 years (range 43-91). 
The median follow-up time was 38 months (range 0-183). 
The data for the patient survival was obtained from 
Statistics Finland, and other relevant data was obtained 
from the patient records (Table 4).
The use of patient samples and the data inquiry 
were approved by the Oulu University Hospital Ethics 
Committee. The need to obtain a written or oral consent 
from the patients for using the samples in research was 
waived by the Finnish National Authority for Medicolegal 
Affairs (VALVIRA, Dnro 10832/06.01.03.01/2014).
Immunohistochemistry
The representative tissue blocks for 
immunohistochemistry were selected by an expert 
gastrointestinal pathologist on the basis of hematoxylin 
and eosin-stained sections, based on presence of 
cytological abnormalities described in detail previously 
[29, 30]. Sections of 5μm were mounted and dewaxed 
in xylene. For antigen retrieval, the sections were heated 
in Tris-EDTA solution (pH 9) for 10 min. Endogenous 
peroxidase activity was blocked using peroxidase-
blocking solution (DAKO, Copenhagen, Denmark) for 10 
min. Incubation with primary antibodies D2 (Tenascin-C) 
and F12 (Fibronectin) in dilution of 1:500 for 60 min at 
room temperature was done. Previously described and 
validated antibodies against Fibronectin and Tenascin 
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C were used [13]. The antibodies were validated by 
comparison to commercially available fibronectin and 
tenascin-C antibodies, as well as using mass spectrometry. 
Horseradish peroxidase (HRP)-conjugated antibodies 
(DAKO) were introduced to sections for 10 min, after 
which DAB chromogen was used for 5 minutes. Slides 
were counterstained with haematoxylin. We validated 
the immunohistochemical analysis through two series 
of negative controls (omitting the primary antibody and 
by replacing primary antibody with the mouse primary 
antibody isotype control).
α-smooth muscle actin (α-SMA) staining with 
primary antibody (Dako monoclonal mouse anti-human, 
1:500, clone 1A4, M0851) for 30min in room temperature 
was performed to 6 patient samples with high (≥3) 
tenascin-C and fibronectin expression, and 6 samples with 
low tenascin-C and fibronectin expression. Double-stains 
of α-SMA, tenascin-C and fibronectin were performed 
by EnVision G|2 Doublestain kit (Dako) according to 
manufacturer’s instructions.
Assessment of tenascin-C and fibronectin 
expression
The hematoxylin and eosin-stained histological 
samples were digitalized using Aperio AT2 Console, 
Leica Biosystems Imaging Inc, Nussloch, Germany. 
Identification and marking of the different lesions in 
the samples were made by an expert gastrointestinal 
pathologist (T.J.K). Immunoreactivity of tenascin-C 
and fibronectin were analyzed by two independent 
researchers who were blinded from the clinical data. 
Non-epithelial (stromal) parts and epithelial cells 
were separately assessed. We analyzed the amount 
and pattern of tenascin-C and fibronectin expression in 
the stroma with a 5 point scale slightly modified from 
that described earlier [10]; 0, no detectable staining; 1, 
focal staining; 2, areas diffuse staining present in less 
than half of stromal area; 3, expression of moderate 
density distributed in more than half but not in all parts 
of the tumor stroma; 4, dense expression extending 
throughout the stroma. The intensity of staining in 
the epithelial cells was estimated on a four point scale 
(0=negative, 1=weak, 2=moderate, 3=strong). We also 
estimated the percentage of the stained epithelial cells 
(0-100%). If there was no difference over 1 in the 
intensity or over 30% in the percentage between the two 
independent estimations, the mean values were used in 
the study. If the difference was greater, re-evaluation 
was performed with a third researcher. However, in the 
current study re-evaluation was not needed in any of the 
samples.
With the cancer lesions we estimated separately 
the stromal expression in tumor bulk and in the invasive 
front of the tumor. The entire area of the target lesion 
was screened and expression was analyzed from area 
of predominant staining. In biopsy samples the invasive 
front of the tumor could not be reliably identified, and 
so the comparison between the tumor stroma and front 
was limited to the resected adenocarcinoma samples 
(n=64).
Assessment of tumor/stroma percentage
Tumor/stroma percentage was evaluated from 
hematoxylin and eosin-stained sections from all carcinoma 
patients (n=90) as described earlier [24]. Percentage (0-
100%) of tumor area in representative microscope view 
from invasive margin was assessed, referred to as tumor/
stroma percentage. Mean value of two independent 
researchers were used with no need for re-evaluation, 
as the interobserver difference was less than 30%. 
Significance of tumor/stroma percentage was analyzed by 
using two (≤50% and >50%) and four (0-25%, 26-50%, 
51-75% and 76-100%) groups.
Assessment of double stains of α-smooth muscle 
actin, tenascin-C and fibronectin
Double stained samples were digitalized similarly 
as described above. Expression of α-SMA was analysed in 
the tumor bulk and in the invasive front of the tumor with 
5-point scale similarly as tenascin-C and fibronectin. The 
overlap of tenascin-C and α-SMA staining was assessed 
in both tumor bulk and invasive front. The overlap 
was reported as percentage (0-100%) of tenascin-C 
positive stroma which contained also α-SMA positivity. 
Fibronectin and α-SMA were analysed with similar 
manner. Mean value of two independent researchers were 
used with no need for re-evaluation.
Immunostaining for CD31 and assessment of 
vascular density
To study correlation of vascular density, tenascin-C 
and fibronectin expression we randomly selected 20 
samples for staining with an antibody to CD31 (M0823, 
clone JC70A, Dakopatts, Glostrup, Denmark) with a 
dilution of 1:200. The slides were counterstained with 
hematoxylin. The mean vascular density was calculated 
as the mean number of positively stained blood vessels in 
high power (20x magnification) field. Any endothelial cell 
cluster consisting of two or more cells was considered a 
single, countable microvessel. Minimum of 10 high power 
fields were analyzed from each tumor and the number of 
microvessels was divided by the number of fields assessed 
to obtain mean vascular density.
Statistical analysis
For statistical analysis we used IBM SPSS 22.0 (IBM 
corp., Armonk, NY, USA). The evaluated mean values of 
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tenascin-C and fibronectin were divided into two different 
categories (low and high ≥3 expression). Due to only 
marginally skewed distributions, we used Oneway ANOVA 
with Tukey in post hoc analysis to compare tenascin-C 
and fibronectin expressions between the different lesions. 
Comparison between tumor stroma and invasive front was 
performed with paired sample T-test. The chi-square test 
was used to calculate statistically significant differences 
between the protein expression and clinicopathological 
variables. Life tables were calculated with the Kaplan-
Meier method and compared between low and high (≥3) 
tenascin-C and fibronectin stromal expression density, 
and tumor/stroma percentage (≤50% and >50% or 0-25%, 
26-50%, 51-75% and 76-100%). Statistical significance 
was assessed with log-rank test. Multivariable analysis 
was done using Cox proportional hazards model with the 
following covariates: T- (1-4), N- (negative or positive), 
M-stage (negative or positive) and tenascin-C expression 
in tumor bulk (low or high; (≥3), using backward stepwise 
selection of variables. P-value of 0.05 was used as the limit 
for inclusion of a covariate. Backward stepwise algorithm 
was used to pick the best combination of prognostic factors 
to explain the mortality in the study population. Correlation 
between stromal tenascin-C, fibronectin, tumor/stroma 
percentage, α-SMA and CD31 were calculated using two-
tailed Spearman’s correlation test.
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